Neurobiological Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Neurobiological Technologies
NTII Stock  USD 0.0001  0.00  0.000003%   
Neurobiological Technologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neurobiological Technologies' valuation are provided below:
Gross Profit
25.3 M
Profit Margin
0.7372
Market Capitalization
2.7 K
Enterprise Value Revenue
0.1885
Revenue
25.3 M
We have found one hundred fourteen available fundamental ratios for Neurobiological Technologies, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Neurobiological Technologies last-minute fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 38.3 M. Enterprise Value is estimated to decrease to about 35.9 M

Neurobiological Technologies Total Revenue

10.98 Million

Check Neurobiological Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobiological Technologies' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 1.3 M or Research Development of 12.9 M, as well as many indicators such as Price To Sales Ratio of 0.75, Dividend Yield of 0.0 or PTB Ratio of 0.84. Neurobiological financial statements analysis is a perfect complement when working with Neurobiological Technologies Valuation or Volatility modules.
  
Build AI portfolio with Neurobiological Stock
Check out the analysis of Neurobiological Technologies Correlation against competitors.
For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.

Neurobiological Technologies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.5 M3.7 M3.6 M
Slightly volatile
Other Current Liabilities1.1 M1.2 M1 M
Slightly volatile
Total Current Liabilities1.1 M1.2 M1 M
Slightly volatile
Total Stockholder Equity1.1 M1.2 M1.7 M
Slightly volatile
Accounts Payable522.5 K565.8 K483.5 K
Slightly volatile
Cash2.6 M2.8 M2.7 M
Slightly volatile
Short Term Investments719.9 K757.8 K852.5 K
Slightly volatile
Other Current Assets437.9 K350.8 K300 K
Slightly volatile
Total Liabilities2.1 M2.2 M1.9 M
Slightly volatile
Preferred Stock Total Equity376.2 K222.3 K305.7 K
Slightly volatile
Common Stock20.4 K31.1 K26.2 K
Pretty Stable
Property Plant Equipment76.5 K80.5 K68.5 K
Slightly volatile
Other Assets44.5 K46.8 K63.7 K
Slightly volatile
Other Liabilities1.2 M1.3 M2.8 M
Slightly volatile
Net Receivables157.3 K165.6 K499.9 K
Slightly volatile
Total Current Assets24 M28.2 M24.6 M
Slightly volatile
Long Term Investments9.5 M10.7 M11.6 M
Slightly volatile

Neurobiological Technologies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative1.3 M1.4 M1.6 M
Slightly volatile
Research Development12.9 M20.2 M16.5 M
Slightly volatile
Total Revenue11 M6.9 M6.3 M
Slightly volatile
Gross Profit6.6 M6.9 M5.8 M
Slightly volatile
Operating Income5.4 M5.1 M4.3 M
Slightly volatile
Income Before Tax6 M5.7 M4.9 M
Slightly volatile
Net Income Applicable To Common Shares6 M5.7 M4.8 M
Slightly volatile
Net Income6 M5.7 M4.8 M
Slightly volatile
Income Tax Expense52.7 K47.7 K52 K
Pretty Stable
Non Recurring810.4 K911.7 K995.1 K
Slightly volatile

Neurobiological Technologies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Operating Activities4.5 M4.3 M4.5 M
Slightly volatile
Net Income6 M5.7 M4.8 M
Slightly volatile
Total Cashflows From Investing Activities18.3 M17.5 M14.6 M
Slightly volatile
Change To Liabilities383.7 K365.4 K395.5 K
Pretty Stable
Investments18.3 M17.5 M14.7 M
Slightly volatile
Depreciation6.8 K7.2 K18.8 K
Slightly volatile
Other Cashflows From Financing Activities43.9 M49.4 M53.9 M
Slightly volatile
Dividends Paid20.1 M22.6 M24.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.750.798.3204
Slightly volatile
PTB Ratio0.840.890.8493
Slightly volatile
Days Sales Outstanding2.782.93205
Slightly volatile
Book Value Per Share0.961.011.7022
Slightly volatile
Average Payables687.7 K654.9 K687 K
Slightly volatile
Stock Based Compensation To Revenue0.05050.02730.0281
Pretty Stable
Capex To Depreciation0.0130.01360.0571
Slightly volatile
PB Ratio0.840.890.8493
Slightly volatile
EV To Sales0.410.437.3455
Slightly volatile
ROIC0.140.130.1435
Pretty Stable
Sales General And Administrative To Revenue0.150.170.189
Slightly volatile
Research And Ddevelopement To Revenue0.730.771.1399
Slightly volatile
Capex To Revenue1.0E-41.0E-40.0085
Slightly volatile
Cash Per Share0.981.030.9992
Slightly volatile
Days Payables Outstanding49.6552.2654.6414
Slightly volatile
Intangibles To Total Assets0.01130.00660.0066
Very volatile
Current Ratio33.431.8134.9709
Slightly volatile
Tangible Book Value Per Share0.961.011.6896
Slightly volatile
Receivables Turnover135129133
Slightly volatile
Shareholders Equity Per Share0.961.011.7022
Slightly volatile
Capex Per Share1.0E-41.0E-40.0064
Slightly volatile
Graham Net Net0.940.991.4862
Slightly volatile
Average Receivables983.6 K936.7 K976.2 K
Slightly volatile
Revenue Per Share0.940.880.9256
Slightly volatile
Interest Debt Per Share0.180.150.1353
Very volatile
Debt To Assets0.640.720.7892
Slightly volatile
Graham Number1.651.741.9304
Slightly volatile
Operating Cycle2.782.93205
Slightly volatile
Price Book Value Ratio0.840.890.8493
Slightly volatile
Days Of Payables Outstanding49.6552.2654.6414
Slightly volatile
Pretax Profit Margin0.110.11850.1306
Slightly volatile
Ebt Per Ebit1.11.030.955
Pretty Stable
Company Equity Multiplier0.981.931.611
Very volatile
Quick Ratio33.431.8134.9709
Slightly volatile
Net Income Per E B T0.790.910.9898
Slightly volatile
Cash Ratio23.8522.7123.8571
Slightly volatile
Days Of Sales Outstanding2.782.93205
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0178
Slightly volatile
Price To Book Ratio0.840.890.8493
Slightly volatile
Fixed Asset Turnover356339351
Slightly volatile
Debt Ratio0.640.720.7892
Slightly volatile
Price Sales Ratio0.750.798.3204
Slightly volatile
Asset Turnover1.010.960.9967
Slightly volatile
Gross Profit Margin0.770.90.9681
Pretty Stable
Price Fair Value0.840.890.8493
Slightly volatile

Neurobiological Technologies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.3 M48.6 M51.2 M
Very volatile
Enterprise Value35.9 M43.7 M46 M
Pretty Stable

About Neurobiological Technologies Financial Statements

Investors use fundamental indicators, such as Neurobiological Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Neurobiological Technologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Revenue6.9 M11 M
Stock Based Compensation To Revenue 0.03  0.05 
Sales General And Administrative To Revenue 0.17  0.15 
Research And Ddevelopement To Revenue 0.77  0.73 
Revenue Per Share 0.88  0.94 
Ebit Per Revenue 0.12  0.13 

Currently Active Assets on Macroaxis

VGIAXVanguard Growth And
XARSPDR SP Aerospace
XARSPDR SP Aerospace
XARSPDR SP Aerospace
ASMLASML Holding NV
When determining whether Neurobiological Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobiological Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobiological Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobiological Technologies Stock:
How To Invest In Neurobiological
Details
Is Neurobiological Stock a good investment?
Details
What is Neurobiological Technologies' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Neurobiological Technologies Correlation against competitors.
For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is there potential for Biotechnology market expansion? Will Neurobiological introduce new products? Factors like these will boost the valuation of Neurobiological Technologies. Anticipated expansion of Neurobiological directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.94
Return On Equity
0.9972
Neurobiological Technologies's market price often diverges from its book value, the accounting figure shown on Neurobiological's balance sheet. Smart investors calculate Neurobiological Technologies' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Neurobiological Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Neurobiological Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurobiological Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY